Cullinan Therapeutics, Inc. Common Stock (CGEM) is a publicly traded Healthcare sector company. As of May 21, 2026, CGEM trades at $14.03 with a market cap of $913.88M and a P/E ratio of 0.00. CGEM moved +0.95% today. Year to date, CGEM is +43.44%; over the trailing twelve months it is +81.39%. Its 52-week range spans $5.68 to $17.98. Analyst consensus is strong buy with an average price target of $30.00. Rallies surfaces CGEM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cullinan’s $393M Cash Runway, Zipalertinib NDA Accepted, CLN-978 Data in June: Cullinan Therapeutics reported Q1 2026 cash and investments of $393.3 million, funding operations into 2029, and R&D spend of $42.1 million. The FDA accepted the zipalertinib NDA for EGFR ex20ins NSCLC with a PDUFA date of February 27, 2027, and CLN-978 clinical data will debut at June's EULAR Congress.
| Metric | Value |
|---|---|
| Price | $14.03 |
| Market Cap | $913.88M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.98 |
| 52-Week Low | $5.68 |
| Volume | 65 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-219.88M |
| Gross Margin | 0.00% |
11 analysts cover CGEM: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.00.